Ratings Myomo, Inc.

Equities

MYO

US62857J2015

Market Closed - Nyse Other stock markets 01:30:00 16/05/2024 am IST			5-day change	1st Jan Change
3.78 ^USD	+5.59%		-3.82%	-24.55%

08/05	Transcript : Myomo, Inc., Q1 2024 Earnings Call, May 08, 2024
08/05	Myomo, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company appears highly valued given the size of its balance sheet.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
MYOMO, INC.	-24.55%	109M	-
ABBOTT LABORATORIES	-4.98%	182B	C+
MEDTRONIC PLC	+2.84%	112B	C
BECTON, DICKINSON AND COMPANY	-2.68%	68.58B	A
DEXCOM, INC.	+4.53%	51.58B	B-
CENCORA, INC.	+8.00%	44.24B	B-
HOYA CORPORATION	+9.45%	43.65B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+25.30%	32.46B	B
TERUMO CORPORATION	+20.94%	25.99B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-0.17%	25.61B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes